Objective To investigate the therapeutic effect of ω-3 polyunsaturated fatty acids (ω3 PUFAs) in treating elderly patients with heart failure with preserved ejection fraction (HFpEF). Methods A total of 108 elderly patients with HFpEF from the Geriatrics Department of our hospital were selected from September 2022 to June 2023 and randomly divided into a control group (n=54) and an observation group (n=54) by a random number table method. The control group received routine heart failure treatment, while the observation group received treatment with ω3PUFAs on this basis. The clinical efficacy was observed between two groups, as well as the cardiac function [left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), interventricular septum thickness (IVST), left ventricular posterior wall thickness (LVPWT)], myocardial injury markers [high-sensitivity troponin T (hs-cTnT), high-sensitivity C-reactive protein (hs-CRP), amino terminal pro-brain natriuretic peptide (NT-proBNP)], inflammatory indicators [interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), pentraxin 3 (PTX-3)], 6 min walking distance (6MWD), activities of daily living (ADL) before and after treatment. The incidence of major adverse cardiovascular events (MACE) in the two groups was also observed in two groups. Results The total effective rate of the observation group was higher than the control group. After 6 months of treatment, the LVEF of the observation group was higher than the control group, LVEDD and LVPWT were lower than the control group. After 6 months of treatment, the serum levels of hs-cTnT, hs-CRP, and NT-proBNP in the observation group were lower than those in the control group. After 6 months of treatment, the levels of serum IL-6, TNF-α, and PTX-3 in the observation group were lower than those in the control group. After 6 months of treatment, the 6MWD and ADL score of the observation group were higher than those of the control group. The incidence of MACE in the observation group was lower than the control group. Conclusion The efficacy of adding ω3PUFAs to conventional heart failure treatment for elderly patients with HFpEF is confirmed. It can improve cardiac function, reduce myocardial damage, inhibit inflammatory response, enhance exercise tolerance and activities of daily living, and decrease the incidence of MACE.
Key words
heart failure with preserved ejection fraction /
ω-3 polyunsaturated fatty acids /
therapeutic effect /
cardiac function /
myocardial damage /
inflammatory response
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] REQUENA-IBANEZ JA, SANTOS-GALLEGO CG, ZAFAR MU, et al.SGLT2-Inhibitors on HFpEF Patients. Role of Ejection Fraction[J]. Cardiovasc Drugs Ther, 2023, 37(5): 989-996.
[2] BONANNI A, VINCI R, D'AIELLO A, et al. Targeting Collagen Pathways as an HFpEF Therapeutic Strategy[J]. J Clin Med, 2023, 12(18): 5862-5872.
[3] 白静, 常国栋, 张晓惠. 沙库巴曲缬沙坦治疗射血分数保留心力衰竭的临床疗效观察[J]. 中国循证心血管医学杂志, 2022, 14(6): 736-738.
[4] 王文静, 王晓玥, 王雅坤. 心通口服液联合瑞舒伐他汀对射血分数保留心力衰竭病人血清可溶性ST2和白细胞介素-33水平的影响[J]. 中西医结合心脑血管病杂志, 2022, 20(8): 1457-1460.
[5] TSENG PT, ZENG BY, ZENG BS, et al.Omega-3 polyunsaturated fatty acids in sarcopenia management: A network meta-analysis of randomized controlled trials[J]. Ageing Res Rev, 2023, 90(1): 102014-102022.
[6] ZAILANI H, SATYANARAYANAN SK, LIAO WC, et al.Roles of Omega-3 Polyunsaturated Fatty Acids in Managing Cognitive Impairment in Chronic Obstructive Pulmonary Disease: A Review[J]. Nutrients, 2023, 15(20): 4363-4371.
[7] 中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789.
[8] 王蔚文. 临床疾病诊断与疗效判断标准[M]. 北京: 科学技术文献出版社, 2010: 161.
[9] NAKANISHI K, YAMAGA T, IKEYA M.Gaps between Activities of Daily Living Performance and Capacity in People with Mild Dementia[J]. Int J Environ Res Public Health, 2022, 19(23): 15949-15958.
[10] CAPONE F, NAMBIAR N, SCHIATTARELLA GG.Beyond Weight Loss: the Emerging Role of Incretin-Based Treatments in Cardiometabolic HFpEF[J]. Curr Opin Cardiol, 2024, 39(3): 148-153.
[11] ROSANO GMC, VITALE C, SPOLETINI I.Precision Cardiology: Phenotype-targeted Therapies for HFmrEF and HFpEF[J]. Int J Heart Fail, 2024, 6(2): 47-55.
[12] 卜星彭, 李春霞, 李丽, 等. 达格列净对老年射血分数保留的心力衰竭的疗效观察[J]. 中华老年心脑血管病杂志, 2022, 24(7): 689-692.
[13] 张小丹, 张巧玲, 朱志勇, 等. 沙库巴曲缬沙坦钠联合常规对症治疗射血分数保留心力衰竭患者的临床疗效及安全性研究[J]. 海南医学, 2024, 35(2): 174-178.
[14] MICHAELOUDES C, CHRISTODOULIDES S, CHRISTODOULOU P, et al.Variability in the Clinical Effects of the Omega-3 Polyunsaturated Fatty Acids DHA and EPA in Cardiovascular Disease-Possible Causes and Future Considerations[J]. Nutrients, 2023, 15(22): 4830-4840.
[15] NOMALI M, HEIDARI ME, AYATI A, et al.Omega-3 supplementation and outcomes of heart failure: A systematic review of clinical trials[J]. Medicine (Baltimore), 2024, 103(3): e36804-e36814.
[16] LAZZARIN T, MARTINS D, BALLARIN RS, et al.The Role of Omega-3 in Attenuating Cardiac Remodeling and Heart Failure through the Oxidative Stress and Inflammation Pathways[J]. Antioxidants (Basel), 2023, 12(12): 2067-2075.
[17] KELLING M, DIMZA M, BARTLETT A, et al.Omega-3 fatty acids in the treatment of heart failure[J]. Curr Probl Cardiol, 2024, 49(9): 102730-102740.
[18] 诸葛瑞琪. ω-3多不饱和脂肪酸防治心血管疾病的研究进展[J]. 中国循环杂志, 2022, 37(5): 543-547.
[19] 李鼎, 王大新. ω-3多不饱和脂肪酸改善心血管预后临床研究进展[J]. 中南医学科学杂志, 2020, 48(6): 655-659.
[20] KOZHUHAROV N, MICHOU E, WUSSLER D, et al.Quantifying Hemodynamic Cardiac Stress and Cardiomyocyte Injury in Normotensive and Hypertensive Acute Heart Failure[J]. Biomedicines, 2024, 12(5): 1099-1107.
[21] WANG ZY, LI GN, HUANG R, et al.Prognostic value of fibrosis-5 index combined with C-reactive protein in patients with acute decompensated heart failure[J]. BMC Cardiovasc Disord, 2023, 23(1): 492-500.
[22] 幸泽茂, 熊丽红, 张宪华, 等. ω-3多不饱和脂肪酸对重症脓毒症心肌损伤的保护作用[J]. 中国医师进修杂志, 2013, 36(22): 9-11.
[23] 张凤梅, 蔡颖, 吴迪, 等. 多不饱和脂肪酸ω-3/多不饱和脂肪酸ω-6与冠状动脉病变相关性研究[J]. 陕西医学杂志, 2023, 52(10): 1326-1330.
[24] ALOGNA A, KOEPP KE, SABBAH M, et al.Interleukin-6 in Patients With Heart Failure and Preserved Ejection Fraction[J]. JACC Heart Fail, 2023, 11(11): 1549-1561.
[25] ZHANG Y, XIONG XY, WANG JQ, et al.Prognostic value of serum IGF-1, Gal-3, and PTX-3 levels in elderly patients with chronic heart failure[J]. Am J Transl Res, 2024, 16(4): 1393-1400.
PDF(2245 KB)
